Cardiol Therapeutics (TSE:CRDL) Announces Earnings Results

Cardiol Therapeutics (TSE:CRDL) released its quarterly earnings results on Monday. The company reported C($0.10) EPS for the quarter, FiscalAI reports.

Cardiol Therapeutics Price Performance

CRDL stock opened at C$1.85 on Wednesday. The stock has a market cap of C$206.61 million, a PE ratio of -4.74 and a beta of 0.24. The company has a debt-to-equity ratio of 0.70, a current ratio of 4.16 and a quick ratio of 6.84. Cardiol Therapeutics has a one year low of C$1.23 and a one year high of C$2.33. The firm has a 50 day simple moving average of C$1.71 and a two-hundred day simple moving average of C$1.52.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.